Nvidia, Eli Lilly to spend $1 billion over five years
Digest more
Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel ...
Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...
Eli Lilly came to the 44 th annual JP Morgan Healthcare Conference bolstered by a strong year. 1 While the looming patent cliff still impacts that company’s upcoming strategy, Lilly found itself in a ...
Wall St. provides estimates for future stock prices of Eli Lilly from 2026 to 2030 based on projected revenue and net income.
The rising popularity of weight loss drugs is a key reason healthcare company Eli Lilly ( LLY 1.31%) has been soaring in ...
France's Finance Ministry said on Monday it had received no formal request for investment approval regarding French biotech ...
Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...
Barchart on MSN
What to Expect From Eli Lilly’s Q4 2025 Earnings Report
Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback